LONDON and PHILADELPHIA – October [12], 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, is pleased to announce that Christina Coughlin, CEO, and Brian Hahn, CFO, will provide a live presentation relating to the Interim Results via Investor Meet Company on 15 Oct 2026, 16:00 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 14 Oct 2026, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Avacta Group Plc via: https://www.investormeetcompany.com/avacta-group-plc/register-investor
Investors who already follow Avacta Group Plc on the Investor Meet Company platform will automatically be invited.